Nirmatrelvir During Acute SARS-CoV-2 Does Not Reduce Risk for Long COVID

FRIDAY, Jan. 5, 2024 -- Treatment with nirmatrelvir during acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is not associated with a reduced risk for subsequent development of long COVID, according to a study published...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news